Budesonide

ITRACONAZOLE PELLETS 22% W/W:

Specifications: White to off white spherical pellets,
Pellets Size:  ASTM16#20: 
Release specification: As per latest USP std.
Fill Weight: 
For 100mg capsule: 455mg pellets filled in SIZE 0 capsules. 1 kg of Pellets can ...

LANSOPRAZOLE Micro PELLETS 12.5%W/W: (Lansoprazole Enteric Coated Micro pellets 12.5%)

Physical Specifications: White to off while spherical pellets, Pellets Size: ASTM 30#50, ASTM 25#50

Release specification: As per latest USP std. including additional parameters i.e. ...

We Murli Krishna Pharma specialised in the manufacture of Pharmaceutical Pellets/ Micro Pellets / Granules and MUPS.We manufacture Lansoprazole Pellets 8.5%( Product complies to USP) Particle size:  ( 14 #18), ( 16 #20) and ( 30 #80) Comparative Dissolution:  The profile matches...

Omeprazole PELLETS 8.5%W/W: (OmeprazoleEnteric Coated pellets 8.5%w/w)


Physical Specifications: 

White to off while spherical pellets, Pellets Size: ASTM 14#18.

Release specification: As per latest USP std. including additional parameters i.e. Related...

The objective of developing Azithromycin taste masked micro pellets (Multiple unit particulate system i.e. MUPS) by aqueous technology is to fill the micro pellets in to capsule, are compressed into tablet and also are constituted to make the oral suspension.

MKPPL developed a Nano particle based matrix which can deliver hydrophilic as well as hydrophobic drugs using a combination of hydrophilic and hydrophobic excipients as a clear solution. This cogent use of excipients ensures that the drug is absorbed optimally and the Nano particles ensure that the dru...

The pharmaceutical form of dexlansoprazole is based on the unique technology of modified dual release. The active ingredient is released in two phases at different pH values and with a time interval. Consequently, the drug achieves two peak concentrations in the blood, and the total serum concentration...

The objective is to develop Duloxetine DR pellets by aqueous technology. Pellets developed by aqueous technology have advantage of avoiding the use of organic solvents

Murli Krishna Pharma developed a Nano particle based premix for direct compression into tablets. The premix was developed using the following approach: 1)            Enhance the solubility of Erlotinib at near neutral pH. 2)  ...

MUPS have distinct advantages over single unit system such as multiple unit particles get distributed throughout the GI tract thereby avoiding localized accumulation. MUPS developed by aqueous technology have also advantage of avoiding the use of organic solvents.

MKPPL is the first to come up with Pellet based approach for Immune Suppressants.  Our pellet based approach reduces the variability of absorption of “LIMUS” based immune suppressants owing to smoother and uniform surface of the particles.

MKPPL have developed safe Nano particles that encapsulate micro nutrients and interact with the outermost layer of skin to enhance penetration and can be delivered through an oil platform. Infant oil massage has been a traditional practice in India. We plan to leverage this practice to implement a tech...

Murli Krishna Pharma Pvt Ltd is a young and dynamic Novel Drug Delivery Systems (NDDS) organization that provides a range of effective solutions to optimize the delivery of pharmaceutical products. Our current activities include manufacturing of pre-finished formulations i.e. Pellets, Granules and MUPS using Aqueous Based technology, Nano Particles and Transdermal Oil.

Tamsulosin HCL SR pellets is developed using an Aqueous platform and our USP lies in complying with all the US Pharmacoepial specifications. With a formulation that is in line with the Innovator product in terms of release profile, We extensively use Extrusion spheronization process besides the wurster process

Murli Krishna Pharma is one of the few companies from India who have developed Albumin bound Paclitaxel. The particle size and the encapsulation efficiency have matched with the innovator’s specifications. In Vitro Cell line studies have shown that the activity is comparable to the innovator.

Leading Manufacturer from India for Orlistat pellets. Offering a product matching the Innovator's release profile, our product does not infringe with the patent.

A Topical administration route had been chosen for the first time for Iron and Vitamins. With Minimal to Zero side effects, the absorption is almost close to 60% when compared to that of the oral route where the absorption is less than 20%. With a strong back up of clinicals on infants, this product of Murli Krishna Pharma is in the process of getting patented